Analyst Price Target is $71.25
▲ +438.14% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $71.25, with a high forecast of $120.00 and a low forecast of $25.00. The average price target represents a 438.14% upside from the last price of $13.24.
Current Consensus is
Buy
The current consensus among 4 polled investment analysts is to buy stock in Cidara Therapeutics. This Buy consensus rating has held steady for over two years.
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More
